Mechanisms of molecular resistance and predictors of response to biological therapy in inflammatory bowel disease

被引：71

作者：

Atreya, Raja

Neurath, Markus F.

机构：

[1] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany

[2] Univ Erlangen Nurnberg, Ludwig Demling Endoscopy Ctr Excellence, Erlangen, Germany

来源：

LANCET GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 3卷 / 11期

关键词：

TUMOR-NECROSIS-FACTOR; SEVERE CROHNS-DISEASE; VEDOLIZUMAB INDUCTION THERAPY; REAL-WORLD EXPERIENCE; C-REACTIVE PROTEIN; ANTI-TNF THERAPY; ULCERATIVE-COLITIS; INFLIXIMAB THERAPY; MAINTENANCE THERAPY; GENE-EXPRESSION;

D O I：

10.1016/S2468-1253(18)30265-6

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Biological therapy has led to marked improvements in treatment of patients with inflammatory bowel disease, and an increasing number of drugs has been approved for treatment. However, only a subgroup of patients responds to therapy, highlighting the need to identify biomarkers for therapeutic response to allow personalised medicine in inflammatory bowel disease. Potential markers of response to biological therapy have been identified; however, studies also suggest that changes in the composition of immune cell infiltrates in response to therapeutic pressure lead to molecular resistance to these drugs. For instance, the cytokine interleukin 23 has been identified as a driver of evasion of apoptosis in response to anti-tumour necrosis factor drugs in patients with Crohn's disease, leading to expansion of apoptosis-resistant T cells and drug resistance. In this Review, we examine the concept of molecular resistance to biological therapy and discuss implications for future therapy.

引用

页码：790 / 802

页数：13

共 100 条

[41] Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort [J].

Khorrami, Sam ;

Ginard, Daniel ;

Marin-Jimenez, Ignacio ;

Chaparro, Maria ;

Sierra, Monica ;

Aguas, Mariam ;

Sicilia, Beatriz ;

Garcia-Sanchez, Valle ;

Suarez, Cristina ;

Villoria, Albert ;

Taxonera, Carlos ;

Velasco-Guardado, Antonio ;

Martinez-Gonzalez, Javier ;

Gisbert, Javier P. .

INFLAMMATORY BOWEL DISEASES, 2016, 22 (07) :1662-1669

[42] Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease [J].

Kiss, L. S. ;

Szamosi, T. ;

Molnar, T. ;

Miheller, P. ;

Lakatos, L. ;

Vincze, A. ;

Palatka, K. ;

Barta, Z. ;

Gasztonyi, B. ;

Salamon, A. ;

Horvath, G. ;

Toth, G. T. ;

Farkas, K. ;

Banai, J. ;

Tulassay, Z. ;

Nagy, F. ;

Szenes, M. ;

Veres, G. ;

Lovasz, B. D. ;

Vegh, Z. ;

Golovics, P. A. ;

Szathmari, M. ;

Papp, M. ;

Lakatos, P. L. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (08) :911-922

[43] Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease [J].

Kopylov, Uri ;

Seidman, Ernest .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (04) :513-526

[44] Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study [J].

Lee, Kang-Moon ;

Jeen, Yoon Tae ;

Cho, Ju Yeon ;

Lee, Chang Kyun ;

Koo, Ja-Seol ;

Park, Dong Il ;

Im, Jong Pil ;

Park, Soo Jung ;

Kim, You Sun ;

Kim, Tae Oh ;

Lee, Suck-Ho ;

Jang, Byung Ik ;

Kim, Ji Won ;

Park, Young Sook ;

Kim, Eun-Soo ;

Choi, Chang Hwan ;

Kim, Hyo Jong .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (12) :1829-1833

[45] Reciprocal Changes of Foxp3 Expression in Blood and Intestinal Mucosa in IBD Patients Responding to Infliximab [J].

Li, Zhe ;

Arijs, Ingrid ;

De Hertogh, Gert ;

Vermeire, Severine ;

Noman, Maja ;

Bullens, Dominique ;

Coorevits, Lieve ;

Sagaert, Xavier ;

Schuit, Frans ;

Rutgeerts, Paul ;

Ceuppens, Jan L. ;

Van Assche, Gert .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (08) :1299-1310

[46] A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism [J].

Louis, E ;

Vermeire, S ;

Rutgeerts, P ;

De Vos, M ;

Van Gossum, A ;

Pescatore, P ;

Fiasse, R ;

Pelckmans, P ;

Reynaert, H ;

D'Haens, G ;

Malaise, M ;

Belaiche, J .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (07) :818-824

[47] Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort [J].

Ma, C. ;

Fedorak, R. N. ;

Kaplan, G. G. ;

Dieleman, L. A. ;

Devlin, S. M. ;

Stern, N. ;

Kroeker, K. I. ;

Seow, C. H. ;

Leung, Y. ;

Novak, K. L. ;

Halloran, B. P. ;

Huang, V. W. ;

Wong, K. ;

Blustein, P. K. ;

Ghosh, S. ;

Panaccione, R. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (09) :1232-1243

[48] Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study [J].

Ma, Christopher ;

Fedorak, Richard N. ;

Kaplan, Gilaad G. ;

Dieleman, Levinus A. ;

Devlin, Shane M. ;

Stern, Nathan ;

Kroeker, Karen I. ;

Seow, Cynthia H. ;

Leung, Yvette ;

Novak, Kerri L. ;

Halloran, Brendan P. ;

Huang, Vivian W. ;

Wong, Karen ;

Blustein, Philip K. ;

Ghosh, Subrata ;

Panaccione, Remo .

INFLAMMATORY BOWEL DISEASES, 2017, 23 (05) :833-839

[49] Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition [J].

Magnusson, Maria K. ;

Strid, Hans ;

Sapnara, Maria ;

Lasson, Anders ;

Bajor, Antal ;

Ung, Kjell-Arne ;

Ohman, Lena .

JOURNAL OF CROHNS & COLITIS, 2016, 10 (08) :943-952

[50] High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment [J].

Magro, Fernando ;

Rodrigues-Pinto, Eduardo ;

Santos-Antunes, Joao ;

Vilas-Boas, Filipe ;

Lopes, Susana ;

Nunes, Amadeu ;

Camila-Dias, Claudia ;

Macedo, Guilherme .

JOURNAL OF CROHNS & COLITIS, 2014, 8 (02) :129-136

← 1 2 3 4 5 6 7 8 9 10 →